Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment
Restricted accessResearch articleFirst published online November, 2018
Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment
HeatonRK, CliffordDB, FranklinDRJr, et al.; CHARTER Group: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 2010; 75:2087–2096.
2.
Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd ed. World Health Organization, Geveva, Switzerland, 2016. Available at http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1, accessed April12, 2018.
3.
AntinoriA, ArendtG, BeckerJT, et al.: Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 2007; 69:1789–1799.
4.
MaQ, VaidaF, WongJ, et al.; CHARTER Group: Long term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol, 2016; 22:170–178.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
